Azenta (AZTA) Competitors

Azenta logo
$47.22 +1.57 (+3.44%)
Closing price 04:00 PM Eastern
Extended Trading
$46.41 -0.81 (-1.72%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AZTA vs. ADPT, SHC, STVN, ALMR, and FTRE

Should you buy Azenta stock or one of its competitors? Azenta's main competitors and comparable companies include Adaptive Biotechnologies (ADPT), Sotera Health (SHC), Stevanato Group (STVN), Alamar Biosciences (ALMR), and Fortrea (FTRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Azenta compare to Adaptive Biotechnologies?

Azenta (NASDAQ:AZTA) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

In the previous week, Azenta had 29 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 46 mentions for Azenta and 17 mentions for Adaptive Biotechnologies. Azenta's average media sentiment score of 0.57 beat Adaptive Biotechnologies' score of 0.26 indicating that Azenta is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Azenta
7 Very Positive mention(s)
6 Positive mention(s)
21 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Adaptive Biotechnologies
6 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Adaptive Biotechnologies has a net margin of -23.67% compared to Azenta's net margin of -26.86%. Azenta's return on equity of 1.41% beat Adaptive Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Azenta-26.86% 1.41% 1.15%
Adaptive Biotechnologies -23.67%-23.95%-8.01%

Azenta currently has a consensus price target of $47.60, suggesting a potential upside of 4.27%. Adaptive Biotechnologies has a consensus price target of $30.31, suggesting a potential upside of 4.38%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Azenta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Azenta
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Adaptive Biotechnologies
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Adaptive Biotechnologies has lower revenue, but higher earnings than Azenta. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Azenta$621.70M3.22-$166.99M-$3.62N/A
Adaptive Biotechnologies$276.98M16.97-$59.50M-$0.45N/A

Azenta has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

99.1% of Azenta shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 10.9% of Azenta shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Adaptive Biotechnologies beats Azenta on 9 of the 16 factors compared between the two stocks.

How does Azenta compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Azenta (NASDAQ:AZTA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Azenta had 44 more articles in the media than Sotera Health. MarketBeat recorded 46 mentions for Azenta and 2 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.04 beat Azenta's score of 0.57 indicating that Sotera Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sotera Health
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Azenta
7 Very Positive mention(s)
6 Positive mention(s)
21 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sotera Health has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, Azenta has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Sotera Health has a net margin of 14.11% compared to Azenta's net margin of -26.86%. Sotera Health's return on equity of 38.46% beat Azenta's return on equity.

Company Net Margins Return on Equity Return on Assets
Sotera Health14.11% 38.46% 7.66%
Azenta -26.86%1.41%1.15%

Sotera Health presently has a consensus target price of $21.14, suggesting a potential upside of 27.29%. Azenta has a consensus target price of $47.60, suggesting a potential upside of 4.27%. Given Sotera Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe Sotera Health is more favorable than Azenta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sotera Health
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
Azenta
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Sotera Health has higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sotera Health$1.16B4.08$77.94M$0.6027.68
Azenta$621.70M3.22-$166.99M-$3.62N/A

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 99.1% of Azenta shares are held by institutional investors. 15.4% of Sotera Health shares are held by insiders. Comparatively, 10.9% of Azenta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Sotera Health beats Azenta on 14 of the 16 factors compared between the two stocks.

How does Azenta compare to Stevanato Group?

Azenta (NASDAQ:AZTA) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Stevanato Group has a net margin of 11.24% compared to Azenta's net margin of -26.86%. Stevanato Group's return on equity of 10.51% beat Azenta's return on equity.

Company Net Margins Return on Equity Return on Assets
Azenta-26.86% 1.41% 1.15%
Stevanato Group 11.24%10.51%6.22%

Stevanato Group has higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Azenta$621.70M3.22-$166.99M-$3.62N/A
Stevanato Group€1.34B3.56€158.21M€0.5827.19

99.1% of Azenta shares are owned by institutional investors. 10.9% of Azenta shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Azenta has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Azenta currently has a consensus price target of $47.60, indicating a potential upside of 4.27%. Given Azenta's higher probable upside, equities research analysts plainly believe Azenta is more favorable than Stevanato Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Azenta
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Stevanato Group
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.67

In the previous week, Azenta had 33 more articles in the media than Stevanato Group. MarketBeat recorded 46 mentions for Azenta and 13 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.34 beat Azenta's score of 0.57 indicating that Stevanato Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Azenta
7 Very Positive mention(s)
6 Positive mention(s)
21 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Stevanato Group
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Stevanato Group beats Azenta on 11 of the 17 factors compared between the two stocks.

How does Azenta compare to Alamar Biosciences?

Azenta (NASDAQ:AZTA) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Azenta has a net margin of -26.86% compared to Alamar Biosciences' net margin of -48.22%. Azenta's return on equity of 1.41% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Azenta-26.86% 1.41% 1.15%
Alamar Biosciences -48.22%-78.71%-20.08%

In the previous week, Azenta had 39 more articles in the media than Alamar Biosciences. MarketBeat recorded 46 mentions for Azenta and 7 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 0.62 beat Azenta's score of 0.57 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Azenta
7 Very Positive mention(s)
6 Positive mention(s)
21 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alamar Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alamar Biosciences has lower revenue, but higher earnings than Azenta. Alamar Biosciences is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Azenta$621.70M3.22-$166.99M-$3.62N/A
Alamar Biosciences$114.05M18.77-$29.82M-$2.15N/A

Azenta presently has a consensus target price of $47.60, suggesting a potential upside of 4.27%. Alamar Biosciences has a consensus target price of $33.00, suggesting a potential upside of 7.11%. Given Alamar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Alamar Biosciences is more favorable than Azenta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Azenta
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Alamar Biosciences
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

99.1% of Azenta shares are owned by institutional investors. 10.9% of Azenta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Azenta beats Alamar Biosciences on 8 of the 14 factors compared between the two stocks.

How does Azenta compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, Azenta had 35 more articles in the media than Fortrea. MarketBeat recorded 46 mentions for Azenta and 11 mentions for Fortrea. Fortrea's average media sentiment score of 0.58 beat Azenta's score of 0.57 indicating that Fortrea is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fortrea
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Azenta
7 Very Positive mention(s)
6 Positive mention(s)
21 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Fortrea has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Azenta has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

99.1% of Azenta shares are owned by institutional investors. 0.7% of Fortrea shares are owned by company insiders. Comparatively, 10.9% of Azenta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Azenta has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortrea$2.72B0.72-$986.20M-$0.73N/A
Azenta$621.70M3.22-$166.99M-$3.62N/A

Fortrea has a net margin of -2.58% compared to Azenta's net margin of -26.86%. Fortrea's return on equity of 13.98% beat Azenta's return on equity.

Company Net Margins Return on Equity Return on Assets
Fortrea-2.58% 13.98% 2.76%
Azenta -26.86%1.41%1.15%

Fortrea currently has a consensus price target of $24.23, suggesting a potential upside of 19.94%. Azenta has a consensus price target of $47.60, suggesting a potential upside of 4.27%. Given Fortrea's stronger consensus rating and higher probable upside, equities research analysts clearly believe Fortrea is more favorable than Azenta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.46
Azenta
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Summary

Fortrea beats Azenta on 11 of the 17 factors compared between the two stocks.

Get Azenta News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZTA vs. The Competition

MetricAzentaLife Sciences Tools & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.07B$10.84B$7.83B$11.75B
Dividend YieldN/A1.45%2.47%4.41%
P/E Ratio-13.0451.5434.3430.11
Price / Sales3.337.098.005.33
Price / Cash8.8526.7921.0222.34
Price / Book1.485.814.763.85
Net Income-$166.99M$57.47B$3.52B$393.14M
7 Day Performance15.31%-5.43%-5.34%-4.53%
1 Month Performance38.52%-0.98%-3.61%-5.86%
1 Year Performance58.72%18.47%0.01%-7.78%

Azenta Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZTA
Azenta
1.9275 of 5 stars
$47.22
+3.4%
$47.60
+0.8%
+53.4%$1.92B$621.70M89.513,000
ADPT
Adaptive Biotechnologies
2.3113 of 5 stars
$30.48
+0.7%
$30.31
-0.6%
+106.0%$4.85B$276.98MN/A624
SHC
Sotera Health
3.6081 of 5 stars
$16.27
+1.6%
$20.88
+28.3%
+6.2%$4.62B$1.16B26.943,000
STVN
Stevanato Group
3.7657 of 5 stars
€13.76
+0.2%
N/A-28.4%€4.17B€1.34B23.726,010
ALMR
Alamar Biosciences
2.2138 of 5 stars
$30.78
+9.7%
$33.00
+7.2%
N/A$2.14B$74.21MN/A222

Related Companies and Tools


This page (NASDAQ:AZTA) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners